MedPath

Spineway Secures GMED Approval for New ESP Prostheses Production Line, Doubles Manufacturing Capacity

2 months ago2 min read

Key Insights

  • Spineway's subsidiary Spine Innovations received GMED approval for a new production line dedicated to LP-ESP and CP-ESP intervertebral disc prostheses, marking a significant strategic milestone for the company.

  • The new production facility in La Rochelle includes a clean room for injection operations and doubles Spineway's manufacturing capacity while securing their supply chain.

  • First LP-ESP prostheses entered production last month with implants from the new line expected to be available by the end of July 2025.

Spineway, a specialist in innovative implants for severe spine disorders, announced that its subsidiary Spine Innovations has received GMED (French notified body) approval for its new production line dedicated to LP-ESP and CP-ESP intervertebral disc prostheses. This regulatory milestone represents a significant strategic achievement for the Group, ensuring secure manufacturing and supply of its innovative ESP prostheses.

New Production Facility Operational

The new production line is located in La Rochelle on the premises of a long-standing Spineway partner and features a clean room specifically designed for injection operations. Following the previously announced schedule, the first LP-ESP prostheses entered production last month, with the first implants from this new line expected to be available by the end of July 2025.
"The approval of this new production line allows us to secure our supply chain while doubling our production capacity," said Stéphane Leroux, CEO of Spineway. "It also reflects our industrial commitment in France and our desire to continue integrating the manufacture of spinal implants."

Strategic Manufacturing Enhancement

The launch of this production line represents the culmination of a three-year development effort led by a dedicated team. This expansion strengthens Spineway's production capacity and enhances the company's unique expertise in manufacturing techniques for intervertebral disc prostheses. The development reinforces the Group's strategic determination to become a major player in less invasive spine treatments.

Company Profile and Market Position

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column. The company maintains an international network of over 50 independent distributors, with more than 70% of its revenue derived from exports, demonstrating its global reach in the spinal implant market.
The GMED approval and production line launch position Spineway to better serve the growing demand for intervertebral disc prostheses while maintaining quality standards required for these critical medical devices used in spine disorder treatment.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.